Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2021 | Pom/dex combinations as salvage for myeloma R/R to dara

Annamaria Brioli • 10 Mar 2021
EMN 2021
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Pomalidomide

Annamaria Brioli, MD, Universitätsklinikum Jena, Jena, Germany, discusses the use of pomalidomide and dexamethasone combinations as salvage therapy for multiple myeloma patients relapsed and/or refractory to daratumumab. This area of research is particularly pertinent, with the use of daratumumab for the treatment of myeloma becoming increasingly widespread. This interview took place during the 2021 European Myeloma Network (EMN) congress.

Disclosures

Annamaria Brioli, MD, receives research founding from Celgene and Honoraria from Janssen, Celgene, Takeda, Amgen and GSK.

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals